查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853288

細胞和基因治療製造服務市場（按服務類型、技術類型、治療領域、應用和最終用戶分類）—2025-2032年全球預測

Cell & Gene Therapy Manufacturing Services Market by Service Type, Technology Type, Therapeutic Area, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因治療製造服務市場將成長至 669.2 億美元，複合年成長率為 16.30%。

關鍵市場統計數據
基準年2024年 199.8億美元
預計年份：2025年 230.6億美元
預測年份 2032 669.2億美元
複合年成長率（%） 16.30%

一篇權威的介紹文章，闡述了細胞和基因治療生產服務為何對臨床成功和商業化策略至關重要。

細胞和基因治療生產服務已從零散的先導計畫發展成為先進治療藥物開發中具有戰略意義的重要組成部分。如今，卓越的生產能力不僅決定臨床應用的速度，也決定複雜生技藥品的商業可行性。本執行摘要整合了營運、技術、監管和商業等各方面的動態因素，這些因素正在改變您制定生產策略和選擇外部合作夥伴的方式。

在整個價值鏈中，分析方法的準確性、供應鏈的可靠性和製程開發的穩健性已成為關鍵的競爭優勢。製造商和服務供應商必須同時應對生物製藥的複雜性、嚴格的監管以及日益全球化的供應商群體。因此，企業主管正優先投資於平台技術、品質系統和整合服務，以降低技術風險並加速臨床試驗進程。

以下各節將探討結構性變化、近期貿易政策介入的影響、細分市場的具體動態、區域差異、企業策略舉措以及對產業領導者的實用建議。每個部分都組裝為評估製造夥伴關係、能力投資和能力發展舉措的組織提供清晰的決策路徑。

技術進步、營運數位化和監管預期如何融合，正迫使細胞和基因治療製造服務產業進行策略轉型

該產業正經歷變革時期，這場變革從根本上改變了治療方法的研發和生產方式。基因編輯技術的進步、病毒和非病毒載體應用範圍的擴大以及精密的分析工具的出現，提高了人們對藥物可重複性和效力的技術期望。同時，基於平台的製程開發和模組化設施設計的轉變，使得在保證產品品質和符合法規要求的前提下，能夠更快地擴大生產規模。

在營運方面，數位化和自動化正在降低關鍵工作流程中的變異性和對勞動力的依賴性。機器學習和流程分析擴大應用於進程內控制和批次放行決策，從而提高批次一致性並加快放行速度。同時，為了接近性患者以及對溫度敏感型物料輸送的物流要求，分散式和混合製造模式正日益受到青睞。

監管參與也在不斷演變，監管機構更加重視生命週期品管、可比較性和長期安全性監測。這促使研發人員、受託製造和監管機構之間需要更緊密的合作，尤其是在研發早期階段。此外，策略資本正流入能夠提供涵蓋載體生產、製程開發和GMP生產等一體化服務的專業合約研發受託製造廠商（ CDMO），這凸顯了市場向端到端提案轉變的趨勢，從而降低了研發專案的風險。

了解美國2025年關稅對全球供應鏈和製造業韌性的多層次營運和策略影響

2025年實施的新關稅進一步加劇了本已複雜的細胞和基因治療生產全球供應鏈的複雜性。進口關稅及相關貿易措施提高了許多進口原料、專用試劑和生產設備的相對成本和前置作業時間。因此，各公司正在重新審視其供應商組合和籌資策略，以降低跨境價格波動帶來的風險。

為此，許多開發商和服務供應商正在加快關鍵投入品的在地化進程，並投資於國內供應商的資格認證，以確保供應的連續性。這些努力通常需要同時在品質保證和法規遵循方面進行投資，以確保替代方案符合嚴格的GMP要求。因此，採購團隊正在投入更多資源用於供應商資格認證、審核準備以及鎖定品質和交付條款的長期合約機制。

契約製造製造商和技術供應商正在調整其商業模式，透過替代採購、遠期採購和合約定價條款來應對關稅帶來的衝擊。此外，貿易措施也強化了區域製造地的策略合理性。區域鄰近性能夠降低關稅的影響，縮短通路，並加強對區域法規結構的遵守。總而言之，關稅的累積影響不僅體現在財務方面，也體現在結構方面，迫使企業重新思考如何組織其製造網路，以增強韌性並符合監管要求。

深度細分洞察揭示了服務類型、技術平台、治療重點、用例和最終用戶需求如何影響服務提供者的定位。

細分市場分析揭示了不同服務類型、技術平台、治療適應症、應用場景和最終用戶類別之間的差異化需求。分析和品管服務、細胞庫服務、諮詢服務、灌裝和包裝服務、GMP生產服務、製程開發服務、法規支援服務、供應鏈和物流服務、技術轉移服務以及載體生產服務等產品類型，各自面臨獨特的能力和產能需求。能夠提供將載體生產與強大的分析和法規支援相結合的整合服務套件的供應商，對尋求透過單一供應商降低風險的開發商更具吸引力。相反，專注於特定服務領域的專業化供應商，可以透過提供卓越的技術深度和客製化解決方案來獲得高階市場定位。

依技術類型分類，可以區分參與基因編輯和載體研發的機構。在基因編輯領域，CRISPR/Cas9、轉錄活化因子樣效應核酸酶（TRAEN）和鋅指核酸酶（ZFNA）等技術各自需要不同的製程開發路徑和監管文件。非病毒載體包括陽離子脂質體、幾丁聚醣基載體、樹狀聚合物、無機奈米顆粒、脂質體、裸露DNA/RNA、肽基載體和聚合物載體，每種載體都有不同的製劑和遞送要求。病毒載體包括腺結合病毒載體、腺病毒載體、單純皰疹病毒載體和逆轉錄病毒載體，這些載體需要專門的生物安全防護、生產平台和效力檢測。能夠展現跨平台專業知識和快速技術轉移能力的公司，將更有利於抓住新的專案需求。

治療領域細分區分了心血管疾病、感染疾病、單藥療法和腫瘤的研發路徑。在心血管疾病領域，針對冠狀動脈疾病和心臟衰竭的項目與針對B型肝炎和愛滋病毒的感染疾病項目相比，其安全性和發行策略有所不同。囊腫纖維化、血友病和鐮狀細胞貧血等單一療法計畫強調治療目的和長期隨訪，因此對載體的生物分佈和持久性有著嚴格的控制。腫瘤項目分為血液系統惡性腫瘤和固態腫瘤，其給藥方案和細胞類型各不相同，導致生產規模和放行標準也存在差異。

基於應用領域的細分區分了臨床生產和商業生產。臨床生產強調小規模生產的靈活性、快速切換和可重複性，而商業生產則需要強大的規模、成本效益和檢驗的高通量分析。最終用戶細分揭示了委外研發機構 ( CRO)、醫院和診所、製藥和生物技術公司以及研究和學術機構之間不同的購買行為和預期能力。 CRO 優先考慮快速週轉和符合監管要求，醫院和診所尋求以患者為中心的本地化解決方案，製藥和生物技術公司重視從開發到商業化的一體化路徑，而研究機構則重視平台存取和技術轉移支援。了解這些細分領域的交集，有助於供應商和申辦者制定符合自身技術優勢、符合買方優先事項和治療需求的提案。

區域對比分析展示了美洲、歐洲、中東和非洲以及亞太地區各自如何影響戰略製造和夥伴關係決策。

區域動態對企業選擇在何處投資產能、與承包商合作以及尋找專業人才有顯著影響。在美洲，由契約製造、學術機構和新創公司組成的密集生態系統為快速轉化路徑提供了支持。這種環境，加上毗鄰龐大的患者群體和資本市場的優勢，鼓勵企業採取垂直整合策略並投資於載體生產能力。

歐洲、中東和非洲呈現異質性格局，卓越中心集中在那些監管環境有利且生物製造基礎設施先進的國家。在歐洲，跨境合作有助於獲取技能嫻熟的勞動力和分析專長，但分散的報銷體系和區域性監管差異要求制定量身定做的打入市場策略。在中東和非洲部分地區，戰略夥伴關係和知識轉移舉措正在興起，這些計劃通常由政府主導的能力建設項目推動。

亞太地區以其快速擴張的製造能力、對生物技術生態系統的大量公共和私人投資以及日益增多的專業製造服務提供者而脫穎而出。多個司法管轄區針對先進治療方法的監管路徑不斷完善，以及該地區的供應鏈優勢（尤其是在試劑和設備製造方面），正促使跨國開發商將亞太地區的生產納入其全球策略。每個地區的監管環境、人才儲備和供應鏈結構都應作為決策依據，用於決定設施選址、外包哪些服務以及如何建立商業夥伴關係以確保長期穩健發展。

決定哪些供應商訂單哪些專案並建立哪些夥伴關係的策略性企業行為和競爭動態

企業行為揭示了一個市場格局：策略差異化源自於能力廣度、技術專長和夥伴關係模式。領先的服務供應商整合了載體生產、製程開發和分析平台的投資，從而提供從早期開發到商業化的一體化路徑。這種能力減少了技術交接環節，降低了專案風險，並吸引了尋求可預測時間表的贊助商。同時，專注於高複雜性細分領域（例如AAV生產、非病毒遞送平台和高級分析）的專業公司，憑藉可重複的技術性能和深厚的監管知識，贏得了高額的委託項目。

策略聯盟和併購是快速獲取自身缺失能力的常用機制，尤其是在企業尋求從提供服務轉型為擁有平台的過程中。外包模式也不斷多元化。一些製藥和生技公司尋求共同投資建造專用設施以確保產能，而有些公司則傾向於靈活的按服務收費協議。品質系統、監管記錄和已證實的技術轉移經驗已成為重要的合約標準。此外，擁有數位化品管系統、完善的批次記錄可追溯性和先進的環境監測技術的公司，憑藉更低的偏差率和更快的監管檢查速度，正在脫穎而出。

競爭格局也凸顯了透明的風險分擔協議、基於里程碑的定價以及能夠協調贊助商和製造商之間獎勵的混合商業模式的重要性。此外，越來越多的公司正在投資永續製造實踐和循環供應鏈計劃，這展現了其長期的營運紀律，並可能影響具有環保意識的贊助商的採購決策。

為產業領導者提供實際的高影響力建議，以加強供應鏈、加速技術轉移並確保製造營運面向未來。

領導者應優先採取一系列切實可行的措施來降低風險、加快研發進度並保障淨利率。首先，應實現關鍵試劑和設備來源多元化，同時尋找二級供應商並建立長期合約保障機制，以降低關稅和供應鏈中斷的影響。此外，還應投資建立強大的分析能力和標準化檢測方法，以縮短技術轉移過程中的資格確認時間，並支援快速提交監管文件。

第二，採用模組化、平台化的流程架構，實現從臨床到商業化的無縫擴展。這包括標準化單元操作、統一文件以及引入數位化流程控制以降低變異性。第三，尋求兼具技術深度和商業性覆蓋範圍的策略夥伴關係關係。將載體生產與下游填充、包裝和分析環節集中進行，可顯著降低交接風險並縮短整體專案週期。

第四，從研發初期就積極與監理機關溝通，合作制定可比性策略、效力檢測法和長期安全性監測計畫。第五，透過有針對性的技能提升計劃，提升員工能力，並專注於GMP最佳實踐、進階分析和設施自動化。第六，在製定區域佈局決策時，應考慮關稅影響、人才供應情況以及與臨床試驗中心的接近性。最後，將永續性指標納入設施規劃和供應商選擇，以降低長期營運風險並滿足相關人員的新期望。

一種透明的混合研究途徑，結合了專家訪談、能力映射和情境檢驗，以支持策略洞察。

這些研究成果基於一種混合方法，結合了專家訪談、技術評估和文件分析。主要資料來源包括對申辦者和醫療服務提供機構的高級製造領導者、品管主管和監管專家進行的結構化訪談，從而深入觀點營運限制和策略重點。這些定性見解與監管指南的技術審查、同行評審文獻和公開資訊進行三角驗證，以檢驗有關技術趨勢和能力的論點。

我們開展了一項詳細的能力映射工作，以評估服務供應商在載體生產、製程開發、GMP生產、分析和法規支援等方面的能力。我們使用平台成熟度、過去的可比性研究和商業規模示範等標準來評估技術的成熟度和可轉移性。供應鏈彈性評估則考慮了供應商集中度、地理分佈和前置作業時間敏感度。

數據驗證包括與第三方技術報告和觀察到的監管結果進行交叉核對。基於情境的分析考慮了在各種貿易和生產能力條件下製造網路和供應商策略的替代配置。調查方法強調透明度和可重複性。研究資料包中包含了訪談通訊協定、產能評估納入標準以及情境參數的依據，並提供給了買方。

本文簡要總結了為何生產能力、監管合規性和供應鏈韌性是成功開發先進療法的關鍵促進因素。

細胞和基因治療製造服務產業正處於曲折點，技術進步、不斷變化的監管環境以及地緣政治主導正在交匯融合，共同塑造戰略選擇。能夠建立模組化、數據驅動流程並確保供應商網路多元化的服務提供者和申辦方，將更有能力應對關稅帶來的不利影響和區域營運的複雜性。儘早與監管機構溝通並建立可驗證的品質體系，仍然是成功進行技術轉移和商業化的必要前提。

各組織必須平衡規模、靈活性和風險降低這三者之間的相互衝突的需求。選擇整合平台策略和目標明確的夥伴關係關係的公司可以加快專案進度並減少專案損耗，而專注於特定領域的專家對於應對高度複雜的技術挑戰仍然至關重要。最終，在製造卓越性日益與治療成功掛鉤的市場中，對流程標準化、勞動力能力和區域韌性的規劃投資將決定企業的競爭力。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合封閉式自動化生物反應器系統進行大規模CAR-T細胞生產，以提高重複性
  • 應用數位雙胞胎和製程分析技術對基因治療生產進行即時監控
  • 利用模組化GMP套件擴展分散式生產網路，以加速區域臨床供應。
  • 病毒載體及細胞基材組成優質原料及供應鏈可追溯性的標準化
  • 採用一次性生產平台，最大限度地減少交叉污染，並提高設施的靈活性。
  • CDMO與學術中心合作開發現成的同種異體細胞療法產品線
  • 關於先進療法藥物療效測試和可比較性的監管協調工作
  • 投資先進的病毒載體純化技術，以提高產量並減少下游瓶頸
  • 利用人工智慧驅動的流程最佳化實現細胞和基因治療生產中的預測性維護和產量比率提升
  • 制定冷凍保存通訊協定和供應鏈物流，以支持活細胞療法的全球分銷

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 細胞和基因治療製造服務市場（按服務類型分類）

  • 分析和品管服務
  • 細胞銀行服務
  • 諮詢服務
  • 灌裝和精加工服務
  • GMP生產服務
  • 流程開發服務
  • 監管支援服務
  • 供應鍊和物流服務
  • 技術轉移服務
  • 向量圖創建服務

9. 按技術類型分類的細胞和基因治療製造服務市場

  • 基因編輯
    • CRISPR/Cas9
    • 轉錄活化因子樣效應核酸酶
    • 鋅指核酸酶
  • 向量
    • 非病毒載體
      • 陽離子脂質
      • 基於幾丁聚醣的載體
      • 樹狀聚合物
      • 無機奈米粒子
      • 脂質體
      • 裸露的DNA/RNA
      • 基於胜肽的載體
      • 聚合物載體
    • 病毒載體
      • 腺結合病毒（AAV）載體
      • 腺病毒載體
      • 單純皰疹病毒（HSV）載體
      • 逆轉錄病毒載體

第10章 按治療領域分類的細胞和基因治療製造服務市場

  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 單基因疾病
    • 囊腫纖維化
    • 血友病
    • 鐮狀細胞貧血症
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤

第11章 細胞與基因療法製造服務市場（按應用領域分類）

  • 臨床生產
  • 商業製造

第12章 細胞和基因治療製造服務市場（按最終用戶分類）

  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究和學術機構

13. 各區域細胞及基因治療製造服務市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 細胞與基因治療製造服務市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國細胞與基因治療製造服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Advanced BioScience Laboratories, Inc. by Institut Merieux
    • AGC Biologics
    • AmplifyBio
    • Bio-Techne Corporation
    • CH Boehringer Sohn AG & Co. KG
    • Catalent, Inc.
    • Cell Therapies Pty Ltd.
    • Cell-Easy
    • Charles River Laboratories International, Inc.
    • Danaher Corporation
    • eXmoor Pharma Concepts Limited
    • FUJIFILM Diosynth Biotechnologies
    • Genezen Laboratories, Inc.
    • Laboratory Corporation of America Holdings
    • Lonza Group AG
    • Merck KGaA
    • Miltenyi Biotec BV & Co. KG
    • Minaris Regenerative Medicine GmbH by Resonac Corporation
    • Nikon Corporation
    • Novartis AG
    • Oxford Biomedica PLC
    • ProPharma Group Holdings, LLC
    • Recipharm AB
    • Samsung Biologics Co., Ltd.
    • SGS SA
    • STEMCELL Technologies Inc.
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • uBriGene Biosciences Inc.
    • WuXi AppTec Co., Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market is projected to grow by USD 66.92 billion at a CAGR of 16.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 19.98 billion
Estimated Year [2025] USD 23.06 billion
Forecast Year [2032] USD 66.92 billion
CAGR (%) 16.30%

An authoritative introduction framing why manufacturing services for cell and gene therapies are now pivotal to clinical success and commercialization strategies

The cell and gene therapy manufacturing services landscape has matured from fragmented pilot projects to a strategically critical component of advanced therapeutics development. Manufacturing excellence now determines not only the speed of clinical translation but also the viability of commercialization for complex biologics. This executive summary synthesizes operational, technological, regulatory, and commercial dynamics that are reshaping how organizations design manufacturing strategies and select external partners.

Across the value chain, precision in analytical methods, reliability in supply chains, and robustness in process development have become decisive competitive differentiators. Manufacturers and service providers must simultaneously manage biologic complexity, regulatory stringency, and an increasingly globalized supplier base. Consequently, senior leaders are prioritizing investments in platform technologies, quality systems, and integrated services that reduce technical risk while accelerating time to clinic.

The following sections examine structural shifts, the implications of recent trade policy interventions, segmentation-specific dynamics, regional contrasts, corporate strategic behaviors, and pragmatic recommendations for industry leaders. Each element is framed to support clear decision-making pathways for organizations evaluating manufacturing partnerships, capacity investments, or capability development initiatives.

How converging technical advances, operational digitization, and regulatory expectations are forcing strategic reinvention across cell and gene therapy manufacturing services

The industry is undergoing transformative shifts that are altering the fundamentals of how therapies are developed and manufactured. Advances in gene editing, expanding use cases for viral and non-viral vectors, and refined analytical tools are raising technical expectations for reproducibility and potency. In tandem, a move toward platform-based process development and modular facility designs is enabling faster scale-up while preserving product quality and regulatory compliance.

Operationally, digitization and automation are reducing variability and labor dependence in critical workflows. Machine learning and process analytics are increasingly applied to in-process controls and batch release decisions, improving lot consistency and accelerating release timelines. At the same time, decentralized and hybrid manufacturing models are gaining traction, driven by the need for geographic proximity to patients and by logistical imperatives for temperature-sensitive material handling.

Regulatory engagement has also evolved; regulators are placing greater emphasis on lifecycle quality management, comparability, and long-term safety monitoring. This has prompted closer collaboration between developers, contract manufacturers, and regulators earlier in development. Finally, strategic capital is flowing into specialized contract development and manufacturing organizations that can offer integrated services across vector production, process development, and GMP manufacturing, underscoring a market-wide shift toward end-to-end propositions that de-risk development programs.

Understanding the layered operational and strategic consequences of the 2025 United States tariff measures on global supply chains and manufacturing resilience

Recent tariff actions introduced in 2025 have created a complex overlay on an already intricate global supply chain for cell and gene therapy manufacturing. Import duties and related trade measures have increased the relative cost and lead time of many imported raw materials, specialized reagents, and manufacturing equipment. As a result, organizations are reassessing supplier portfolios and procurement strategies to mitigate exposure to cross-border pricing volatility.

In response, many developers and service providers have accelerated localization of critical inputs and invested in qualifying domestic suppliers to secure continuity of supply. These efforts often require parallel investments in quality assurance and regulatory alignment to ensure substitutes meet stringent GMP expectations. Consequently, procurement teams are devoting more resources to supplier qualification, audit readiness, and long-term contracting mechanisms that lock in quality and delivery terms.

Contract manufacturers and technology vendors are adjusting commercial models to absorb some tariff-related friction through alternative sourcing, forward purchasing, and contractual pricing clauses. Moreover, trade measures have intensified the strategic rationale for regional manufacturing footprints, where proximity reduces tariff exposure, shortens distribution pathways, and enhances compliance with local regulatory frameworks. Taken together, the cumulative impact of tariffs is not only financial but also structural, prompting organizations to rethink how manufacturing networks should be organized for resilience and regulatory congruence.

Deep segmentation insights that reveal how distinct service types, technology platforms, therapeutic focuses, applications, and end-user needs shape provider positioning

Segmentation analysis reveals differentiated imperatives across service types, technology platforms, therapeutic indications, application contexts, and end-user categories. Service types such as Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services each face unique capability and capacity demands. Providers offering integrated suites that combine vector production with robust analytics and regulatory support achieve greater appeal to developers seeking single-vendor risk reduction. Conversely, highly specialized providers that concentrate on a narrow set of services can secure premium positioning by delivering superior technical depth and bespoke solutions.

Technology type segmentation differentiates organizations working in Gene Editing and Vectors. Within Gene Editing, approaches such as CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases require distinct process development pathways and regulatory dossiers. Vector technologies split into Non-Viral and Viral Vectors; Non-Viral Vectors encompass cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, each with divergent formulation and delivery considerations. Viral Vectors include adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, and these necessitate specialized containment, production platforms, and potency assays. Firms that can demonstrate cross-platform expertise or rapid transferability between these technology types are better positioned to capture emerging program demand.

Therapeutic area segmentation distinguishes development pathways across cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Within cardiovascular diseases, programs focused on coronary artery disease and heart failure require distinct safety and delivery strategies compared with infectious disease programs targeting hepatitis B or HIV. Monogenic disorder efforts such as cystic fibrosis, hemophilia, and sickle cell anemia emphasize curative intent and long-term follow-up, imposing rigorous controls on vector biodistribution and persistence. Oncology programs, split between hematological malignancies and solid tumors, demand divergent manufacturing scales and release criteria due to differing dosing paradigms and cell types.

Application-based segmentation differentiates clinical manufacturing from commercial manufacturing. Clinical manufacturing emphasizes flexibility, rapid changeover, and small-batch reproducibility, while commercial manufacturing demands robust scale, cost efficiencies, and validated high-throughput analytics. End-user segmentation highlights the varied buying behaviors and capability expectations of contract research organizations, hospitals & clinics, pharmaceutical & biotech companies, and research institutes & academic institutions. CROs prioritize rapid turnaround and regulatory alignment, hospitals and clinics seek localized solutions for patient-centric delivery, pharmaceutical and biotech companies emphasize integrated development-to-commercial pathways, and research institutes focus on platform access and technology transfer support. Understanding these intersecting segmentation layers enables providers and sponsors to tailor propositions that align technical strengths with buyer priorities and therapeutic requirements.

Comparative regional intelligence explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape strategic manufacturing and partnership decisions

Regional dynamics materially influence where organizations choose to invest in capacity, partner with contractors, and locate specialized capabilities. In the Americas, a dense ecosystem of contract manufacturers, academic spinouts, and venture-backed developers supports rapid translational pathways, while regulatory agencies are offering increasingly mature guidance frameworks for advanced therapies. This environment encourages vertically integrated strategies and investments in vector production capacity, given the proximity to large patient populations and capital markets.

Europe, the Middle East & Africa present a heterogeneous landscape, with centers of excellence clustered in countries that combine favorable regulatory clarity with advanced biomanufacturing infrastructure. Cross-border collaborations within Europe facilitate access to skilled labor and analytic expertise, yet fragmented reimbursement and localized regulatory nuances require tailored market entry strategies. In parts of the Middle East and Africa, strategic partnerships and knowledge transfer initiatives are emerging, often driven by government-led capacity-building programs.

Asia-Pacific stands out for rapid expansion of manufacturing capacity, significant public and private investment in biotech ecosystems, and a growing cadre of specialized manufacturing service providers. Regulatory pathways in several jurisdictions are evolving to accommodate advanced therapies, and regional supply chain advantages-particularly in reagents and equipment manufacturing-are prompting multinational developers to consider Asia-Pacific-based production as part of global strategies. Each region's regulatory posture, talent availability, and supply chain topology should inform decisions about where to site facilities, which services to insource, and how to structure commercial partnerships for long-term resilience.

Strategic company behaviors and competitive dynamics that determine which providers are winning mandates and how partnerships are being structured

Corporate behaviors reveal a market in which strategic differentiation emerges from capability breadth, technological specialization, and partnership models. Leading service providers are combining investments in vector production, process development, and analytical platforms to offer integrated pathways from early development through commercialization. These capabilities reduce technical handoffs and lower program risk, attracting sponsors seeking predictable timelines. At the same time, specialized firms that focus on high-complexity niches-such as AAV manufacturing, non-viral delivery platforms, or advanced analytics-are capturing premium mandates by demonstrating reproducible technical performance and deep regulatory know-how.

Strategic alliances and M&A activity are common mechanisms for acquiring missing capabilities rapidly, particularly when organizations aim to move from service provision to platform ownership. Outsourcing models continue to diversify; some pharmaceutical and biotech companies pursue co-investment in dedicated facilities to secure capacity, while others prefer flexible, fee-for-service engagements. Quality systems, regulatory track records, and demonstrated technology transfer experience are decisive contracting criteria. Additionally, firms that adopt digital quality management systems, robust batch record traceability, and advanced environmental monitoring differentiate themselves through lower deviation rates and faster regulatory inspections.

The competitive landscape also values transparent risk-sharing agreements, milestone-based pricing, and hybrid commercial structures that align incentives between sponsors and manufacturers. Finally, a growing subset of companies is investing in sustainable manufacturing practices and circular supply chain initiatives, which signal long-term operational discipline and can influence procurement decisions among environmentally conscious sponsors.

Practical high-impact recommendations for industry leaders to fortify supply chains, accelerate technology transfer, and future-proof manufacturing operations

Leaders should prioritize a set of actionable measures that reduce risk, accelerate development timelines, and protect margins. First, diversify sourcing for critical reagents and equipment while qualifying secondary suppliers and establishing long-term contractual safeguards to mitigate tariff and supply chain disruptions. Parallel to this, invest in robust analytical capability and standardized assays to shorten qualification timelines during technology transfer and to support faster regulatory submissions.

Second, adopt modular and platform-focused process architectures that enable seamless scale transitions from clinical to commercial contexts. This includes standardizing unit operations, harmonizing documentation, and embedding digital process controls to lower variability. Third, pursue strategic partnerships that combine technical depth with commercial reach; co-locating vector production with downstream fill-and-finish or analytics can materially reduce handoff risks and improve overall program timelines.

Fourth, engage proactively with regulators earlier in development to align on comparability strategies, potency assays, and long-term safety monitoring. Fifth, enhance workforce competency through targeted upskilling programs focused on GMP best practices, advanced analytics, and equipment automation. Sixth, consider regional footprint decisions through the lens of tariff exposure, talent availability, and proximity to clinical sites. Finally, incorporate sustainability metrics into facility planning and supplier selection to reduce long-term operational risk and to meet emerging stakeholder expectations.

A transparent hybrid research approach blending primary expert interviews, capability mapping, and scenario validation to underpin strategic insights

The research underpinning these insights relied on a hybrid methodology that combined expert interviews, technology assessments, and documentary analysis. Primary inputs included structured interviews with senior manufacturing leaders, quality heads, and regulatory experts across sponsor and provider organizations, which provided granular perspectives on operational constraints and strategic priorities. These qualitative insights were triangulated with technical reviews of regulatory guidance, peer-reviewed literature, and public disclosures to validate technology trends and capability claims.

A detailed capability-mapping exercise assessed service providers across vector production, process development, GMP manufacturing, analytics, and regulatory support. Technology readiness and transferability were evaluated through criteria such as platform maturity, historical comparability studies, and demonstrated commercial-scale runs. Supply chain resilience assessments considered supplier concentration, geographic exposure, and lead-time sensitivities.

Data validation included cross-referencing interview findings with third-party technical reports and observed regulatory outcomes. Scenario-based analysis explored alternative configurations for manufacturing networks and supplier strategies under varying trade and capacity conditions. The methodology emphasized transparency and reproducibility: documentation of interview protocols, inclusion criteria for capability assessments, and the rationale for scenario parameters are available to buyers as part of the research package.

A concise concluding perspective on why manufacturing capability, regulatory alignment, and supply chain resilience will determine success in advanced therapy development

The cell and gene therapy manufacturing services sector stands at an inflection point where technical progress, regulatory evolution, and geopolitical influences collectively shape strategic choices. Providers and sponsors that build modular, analytics-driven processes and secure diversified supplier networks will be better equipped to navigate tariff-driven headwinds and regional operational complexities. Early regulatory engagement and demonstrable quality systems remain non-negotiable prerequisites for successful technology transfer and commercialization.

Organizations must balance the competing imperatives of scale, flexibility, and risk reduction. Those that opt for integrated platform strategies or targeted partnerships can shorten timelines and lower program attrition, while specialists that concentrate on niche capabilities will continue to be essential for addressing high-complexity technical challenges. Ultimately, deliberate investments in process standardization, workforce capability, and regional resilience will determine competitive positioning in a market where manufacturing excellence increasingly equals therapeutic success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of closed automated bioreactor systems for large-scale CAR-T production to enhance reproducibility
  • 5.2. Implementation of digital twin and process analytical technology for real-time monitoring of gene therapy manufacturing
  • 5.3. Expansion of decentralized manufacturing networks using modular GMP suites to accelerate regional clinical supply
  • 5.4. Standardization of raw material quality and supply chain traceability for viral vector and cell substrate components
  • 5.5. Adoption of single-use manufacturing platforms to minimize cross-contamination and improve facility flexibility
  • 5.6. Collaboration between CDMOs and academic centers for development of off-the-shelf allogeneic cell therapy pipelines
  • 5.7. Regulatory harmonization efforts addressing potency assays and comparability for advanced therapy medicinal products
  • 5.8. Investment in advanced viral vector purification technologies to increase yield and reduce downstream bottlenecks
  • 5.9. Use of AI-driven process optimization for predictive maintenance and yield improvement in cell and gene therapy manufacturing
  • 5.10. Development of cryopreservation protocols and supply chain logistics to support global distribution of living cell therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Manufacturing Services Market, by Service Type

  • 8.1. Analytical & Quality Control Services
  • 8.2. Cell Banking Services
  • 8.3. Consulting Services
  • 8.4. Fill & Finish Services
  • 8.5. GMP Manufacturing Services
  • 8.6. Process Development Services
  • 8.7. Regulatory Support Services
  • 8.8. Supply Chain & Logistics Services
  • 8.9. Technology Transfer Services
  • 8.10. Vector Production Services

9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

  • 9.1. Gene Editing
    • 9.1.1. CRISPR/Cas9
    • 9.1.2. Transcription Activator-Like Effector Nucleases
    • 9.1.3. Zinc Finger Nucleases
  • 9.2. Vectors
    • 9.2.1. Non-Viral Vectors
      • 9.2.1.1. Cationic Lipids
      • 9.2.1.2. Chitosan-Based Vectors
      • 9.2.1.3. Dendrimers
      • 9.2.1.4. Inorganic Nanoparticles
      • 9.2.1.5. Liposomes
      • 9.2.1.6. Naked DNA/RNA
      • 9.2.1.7. Peptide-Based Vectors
      • 9.2.1.8. Polymeric Vectors
    • 9.2.2. Viral Vectors
      • 9.2.2.1. Adeno-Associated Virus (AAV) Vectors
      • 9.2.2.2. Adenovirus Vectors
      • 9.2.2.3. Herpes Simplex Virus (HSV) Vectors
      • 9.2.2.4. Retrovirus Vectors

10. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

  • 10.1. Cardiovascular Diseases
    • 10.1.1. Coronary Artery Disease
    • 10.1.2. Heart Failure
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis B
    • 10.2.2. HIV
  • 10.3. Monogenic Disorders
    • 10.3.1. Cystic Fibrosis
    • 10.3.2. Hemophilia
    • 10.3.3. Sickle Cell Anemia
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Solid Tumors

11. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 11.1. Clinical Manufacturing
  • 11.2. Commercial Manufacturing

12. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotech Companies
  • 12.4. Research Institutes & Academic Institutions

13. Cell & Gene Therapy Manufacturing Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Manufacturing Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Manufacturing Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Advanced BioScience Laboratories, Inc. by Institut Merieux
    • 16.3.2. AGC Biologics
    • 16.3.3. AmplifyBio
    • 16.3.4. Bio-Techne Corporation
    • 16.3.5. C.H. Boehringer Sohn AG & Co. KG
    • 16.3.6. Catalent, Inc.
    • 16.3.7. Cell Therapies Pty Ltd.
    • 16.3.8. Cell-Easy
    • 16.3.9. Charles River Laboratories International, Inc.
    • 16.3.10. Danaher Corporation
    • 16.3.11. eXmoor Pharma Concepts Limited
    • 16.3.12. FUJIFILM Diosynth Biotechnologies
    • 16.3.13. Genezen Laboratories, Inc.
    • 16.3.14. Laboratory Corporation of America Holdings
    • 16.3.15. Lonza Group AG
    • 16.3.16. Merck KGaA
    • 16.3.17. Miltenyi Biotec B.V. & Co. KG
    • 16.3.18. Minaris Regenerative Medicine GmbH by Resonac Corporation
    • 16.3.19. Nikon Corporation
    • 16.3.20. Novartis AG
    • 16.3.21. Oxford Biomedica PLC
    • 16.3.22. ProPharma Group Holdings, LLC
    • 16.3.23. Recipharm AB
    • 16.3.24. Samsung Biologics Co., Ltd.
    • 16.3.25. SGS S.A.
    • 16.3.26. STEMCELL Technologies Inc.
    • 16.3.27. Takara Bio Inc.
    • 16.3.28. Thermo Fisher Scientific Inc.
    • 16.3.29. uBriGene Biosciences Inc.
    • 16.3.30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZ